We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Reata Pharmaceuticals Inc | NASDAQ:RETA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 172.36 | 189.75 | 172.36 | 0 | 01:00:00 |
Second quarter financial results to be discussed during the call will be included in an earnings press release that will be available on the company’s website shortly before the call at http://news.reatapharma.com and will be available for 12 months after the call. The webcast can be accessed on the Investors & News section of the company’s website. The conference call can be accessed by dialing (844) 348-3946 (toll-free domestic) or (213) 358-0892 (international) and using conference ID 4089166. An archived replay of the webcast will be available on the company’s website shortly after the event and for 90 days after the call.
About Reata Pharmaceuticals, Inc.
Reata is a clinical-stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways involved in the regulation of cellular metabolism and inflammation. Reata’s two most advanced clinical candidates, bardoxolone methyl and omaveloxolone, target the important transcription factor Nrf2 that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling.
Contact:Reata Pharmaceuticals, Inc.(972) 865-2219info@reatapharma.comhttp://news.reatapharma.com
Investor Relations:Vinny JindalVice President, Strategy(469) 374-8721ir@reatapharma.com
Media:Matt Middleman, M.D.LifeSci Public Relations(646) 627-8384matt.middleman@lifescipublicrelations.com
1 Year Reata Pharmaceuticals Chart |
1 Month Reata Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions